Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001090531 | SCV001246135 | pathogenic | not provided | 2017-08-01 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001847151 | SCV002106227 | uncertain significance | Hereditary spastic paraplegia | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001090531 | SCV003827450 | uncertain significance | not provided | 2020-12-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003502587 | SCV004297095 | pathogenic | Hereditary spastic paraplegia 3A | 2022-10-26 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Gly409 amino acid residue in ATL1. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ATL1 protein function. ClinVar contains an entry for this variant (Variation ID: 870859). This missense change has been observed in individual(s) with spastic paraplegia (PMID: 25193411). In at least one individual the variant was observed to be de novo. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 409 of the ATL1 protein (p.Gly409Asp). |